← Back to headlines
Piper Sandler Reaffirms Moderna Stock Rating Following Flu Vaccine Approval
Piper Sandler has reiterated its stock rating for Moderna after the company received approval for its flu vaccine.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Frankfurt's Bahnhofsviertel Restaurateurs Face Challenges, City Urged to Provide Support
23m ago
Efteling's Refillable Soft Drinks Sell Out After Foodwatch Critique
34m ago
FAA Mandates Inspection of 1500 Boeing 737 Max Due to Crack Risks
39m ago
Technology Drives Transformation of Nigeria Customs Service
42m ago